Genetic Variations in RGS Genes and Survival in Late-Stage Lung Cancer
Author Information
Author(s): Dai Jingyao, Gu Jian, Lu Charles, Lin Jie, Stewart David, Chang David, Roth Jack A., Wu Xifeng
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Genetic variations in RGS gene family may be associated with the response of late-stage non-small cell lung cancer (NSCLC) patients to chemotherapy or chemoradiotherapy.
Conclusion
The study found that certain genetic variations in RGS genes are significantly associated with overall survival in late-stage NSCLC patients.
Supporting Evidence
- Thirteen SNPs were significantly associated with overall survival.
- Stratified analysis identified SNPs associated with survival in chemotherapy and chemoradiotherapy groups.
- A significant cumulative effect was observed when these SNPs were combined.
- Survival tree analyses identified potential interactions between SNPs affecting survival time.
Takeaway
This study looked at how changes in specific genes might affect how long people with advanced lung cancer live after treatment.
Methodology
The study genotyped 95 tagging single nucleotide polymorphisms (SNPs) in 17 RGS genes in 598 late-stage NSCLC patients and analyzed their association with overall survival.
Potential Biases
Potential biases may arise from the single-institution study design and the specific population sampled.
Limitations
The study is observational and may not establish causation; further validation in independent studies is needed.
Participant Demographics
The mean age of participants was 59.7 years, with a mix of genders and ethnicities.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI for significant SNPs ranged from 0.22 to 4.44.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website